AstraZeneca: Tagrisso for Adult Patients with Early-Stage EGFRm NSCLC...
AstraZeneca (AZN): Tagrisso (osimertinib) has been recommended for marketing authorization in the European Union for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung . . .
This content is for paid subscribers.
Impacting News
April 27, 2021
